New medications for substance use disorders: challenges and opportunities
- PMID: 22157859
- PMCID: PMC3238092
- DOI: 10.1038/npp.2011.84
New medications for substance use disorders: challenges and opportunities
Abstract
An increased understanding of the biological mechanisms underlying the process of addiction has led to unique molecular targets and strategies for pharmacotherapies against addiction. However, the successful translation of these discoveries will require: 1) a more active engagement of the pharmaceutical sector, 2) partnership with regulatory agencies to arrive at meaningful outcomes for medication approval and 3) a greater involvement of the healthcare system in the screening and treatment of substance use disorders.
References
-
- Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci. 2011;1216:144–166. - PubMed
-
- NAS 1995The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and the Private SectorIn: Fulco CE, Liverman CT, and Earley LE (eds).Board on Biobehavioral Health and Mental Disorders National Academy Press: Washington, DC; pp 43–200. - PubMed
-
- ONDCP 2004The Economic Costs of Drug Abuse in the United States Executive Office of the President Office of National Drug Control Policy: Washington, DC; http://www.ncjrs.gov/ondcppubs /publications/pdf/economic_costs.pdf .
